Recruiting

Testing a new immune-boosting treatment for advanced melanoma

Plain-English translation of NCT06940739 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This is the first study in humans testing a new medication called , which is designed to boost your immune system to fight melanoma. The medication combines an immune-boosting protein with an antibody to help your body recognize and attack cancer cells. You would receive this medication either before or after another type of treatment called lifileucel, depending on which part of the study you join.

Many people with advanced melanoma stop responding to current standard treatments. Researchers believe that by adding this new immune-boosting medication to existing therapies, they may be able to help more patients fight their cancer effectively.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with melanoma that cannot be surgically removed or has spread to other parts of your body
your melanoma has gotten worse despite treatment with certain standard immunotherapy drugs, or it progressed within 12 weeks of stopping those drugs
you are in good enough health to participate, with an expected survival of more than 6 months
you have recovered from side effects of all your previous cancer treatments

You likely don't qualify if…

you have untreated cancer that has spread to your brain and is causing symptoms
you have a weakened immune system, active infection risk, blood clotting problems, or serious heart, lung, or breathing problems
you have a history of severe allergic reactions to the components of this medication
you have had another type of cancer in the last 3 years
you are taking high-dose steroid medications or have had an organ transplant in the past 20 years

What participation looks like

The study has two main parts. In one part, you would receive the new medication before starting lifileucel treatment. In the other part, you would receive the medication after lifileucel instead of a standard immune-boosting drug that's normally used. Your doctors will monitor you closely with blood tests, imaging scans, and regular check-ins to watch for side effects and how well the treatment is working. The study involves 42 participants total and is actively recruiting patients now.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(5 sites)

United States

SCRI Oncology Partners- Denver, Denver, Colorado

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Sarah Cannon Research Institute, Nashville, Tennessee

Australia

Greenslopes Private Hospital, Greenslopes, Queensland

Hollywood Private Hospital Ramsay, Nedlands, Western Australia